Kazia Therapeutics Annual Report 2021

PARTNERING LIES AT THE HEART OF KAZIA’S BUSINESS MODEL, AND THE TRANSACTIONS DURING FY2021 DEMONSTRATE THAT THIS IS NOT MERELY AN ASPIRATION BUT AN IMPORTANT AND HIGHLY DIFFERENTIATING ABILITY OF THE COMPANY. 4 CHAIRMAN’S LETTER Dear Shareholder, The end of the 2021 financial year finds Kazia in very robust health, with dramatic progress reported across every aspect of our business: clinical development, partnering, and financing. It is a pleasure to take this opportunity to review some of the most significant milestones of this past year. FINANCIAL PERFORMANCE Our cash balance at 30 June 2021 was $27.6 million, versus $8.8 million at 30 June 2020. Our total assets were $58.1m, up from $23.1 million at 30 June 2020. We committed outlays of $23.9m of which 80% was devoted directly to investment in R&D. Kazia Therapeutics Limited BUILDING VALUE